EMA/871494/2022

European Medicines Agency decision

P/0487/2022

of 2 December 2022

on the refusal of a modification of an agreed paediatric investigation plan for encorafenib (Braftovi), (EMEA-001588-PIP01-13-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.

European Medicines Agency decision

P/0487/2022

of 2 December 2022

on the refusal of a modification of an agreed paediatric investigation plan for encorafenib (Braftovi), (EMEA-001588-PIP01-13-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0054/2016 issued on 18 March 2016, and decision P/0071/2018 issued on 16 March 2018,

Having regard to the application submitted by Pierre Fabre Médicament on 1 July 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 October 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the refusal of changes to the agreed paediatric investigation plan and to the deferral and to the waiver.

(2) It is therefore appropriate to adopt a decision on the refusal of changes to the agreed paediatric investigation plan, including changes to the deferral and to the waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for encorafenib (Braftovi), capsule, hard, age-appropriate oral dosage form, including changes to the deferral and to the waiver, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, are hereby refused.

Article 2

This decision is addressed to Pierre Fabre Médicament, Les Cauquillous, 81500 – Lavaur, France.

EMA/PDCO/657771/2022 Corr[1]
Amsterdam, 14 October 2022

Opinion of the Paediatric Committee on the refusal of a modification of an agreed Paediatric Investigation Plan

EMEA-001588-PIP01-13-M02

Scope of the application

Active substance(s):

Encorafenib

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of melanoma

Pharmaceutical form(s):

Capsule, hard

Age-appropriate oral dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Pierre Fabre Médicament

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Pierre Fabre Médicament submitted to the European Medicines Agency on 1 July 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0054/2016 issued on 18 March 2016, and decision P/0071/2018 issued on 16 March 2018.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral and changes to the waiver to cover the remaining subsets of the paediatric population.

[1] 2 December 2022.

The procedure started on 16 August 2022.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends, as set out in the appended summary report:

   - to refuse the changes proposed by the applicant regarding the paediatric investigation plan and the deferral and the scope of the waiver.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s)) covered by the waiver remain unchanged and are set out in the Annex I.

3. The scientific conclusions and the grounds for refusal are set out in the summary report appended to this opinion.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of melanoma

The waiver applies to:

- the paediatric population from birth to less than 12 years of age;
- capsule, hard, age-appropriate oral dosage form, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition

Treatment of melanoma

2.1.1. Indication(s) targeted by the PIP

Encorafenib in combination with binimetinib is indicated for the treatment of patients aged 12 years and older with unresectable or metastatic melanoma harbouring BRAF V600 mutations

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 12 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

Age-appropriate oral dosage form

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an oral age-appropriate formulation.
Non-clinical studies	Not applicable.
Clinical studies	**Study 2** Multicentre, open-label study to assess pharmacokinetics, safety, tolerability, and preliminary evidence of antitumor activity of the combination of binimetinib and encorafenib in adolescents from 12 to 18 years with unresectable or metastatic BRAF V600 mutant melanoma (same as in PIP EMEA-001454-PIP03-15).

Extrapolation, modelling and simulation studies	**Study 3** Modelling and simulation study to evaluate the use of the product in the treatment of melanoma in adolescents from 12 to less than 18 years of age with unresectable or metastatic BRAF V600 mutant melanoma (same as in PIP EMEA-001454-PIP03-15).
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of melanoma

Authorised indication(s):

- Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
  - Invented name(s): Braftovi
  - Authorised pharmaceutical form(s): Hard capsule
  - Authorised route(s) of administration: Oral use
  - Authorised via centralised procedure